The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy

od Laack, Nadia N, Pugh, Stephanie L, Brown, Paul D, Fox, Sherry, Wefel, Jeffrey S, Meyers, Christina, Choucair, Ali, Khuntia, Deepak, Suh, John H, Roberge, David, Wendland, Merideth M, Bruner, Deborah
Izdano u Neurooncol Pract (2019)

Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes

od Hall, William A, Pugh, Stephanie L, Wefel, Jeffrey S, Armstrong, Terri S, Gilbert, Mark R, Brachman, David G, Werner-Wasik, Maria, Wendland, Merideth M, Brown, Paul D, Chao, Samuel T, Roof, Kevin S, Robins, H Ian, Mehta, Minesh P, Curran, Walter J, Movsas, Benjamin
Izdano u Neurosurgery (2019)

A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913

od Chinnaiyan, Prakash, Won, Minhee, Wen, Patrick Y, Rojiani, Amyn M, Werner-Wasik, Maria, Shih, Helen A, Ashby, Lynn S, Michael Yu, Hsiang-Hsuan, Stieber, Volker W, Malone, Shawn C, Fiveash, John B, Mohile, Nimish A, Ahluwalia, Manmeet S, Wendland, Merideth M, Stella, Philip J, Kee, Andrew Y, Mehta, Minesh P
Izdano u Neuro Oncol (2018)

Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Gr...

od Blumenthal, Deborah T, Won, Minhee, Mehta, Minesh P, Gilbert, Mark R, Brown, Paul D, Bokstein, Felix, Brachman, David G, Werner-Wasik, Maria, Hunter, Grant K, Valeinis, Egils, Hopkins, Kirsten, Souhami, Luis, Howard, Steven P, Lieberman, Frank S, Shrieve, Dennis C, Wendland, Merideth M, Robinson, Cliff G, Zhang, Peixin, Corn, Benjamin W
Izdano u Neuro Oncol (2018)

NRG/RTOG 1122: phase II double-blinded, placebo-controlled study of bevacizumab with/without trebananib in patients with recurrent glioblastoma or gliosarcoma

od Lee, Eudocia Q, Zhang, Peixin, Wen, Patrick Y, Gerstner, Elizabeth R, Reardon, David A, Aldape, Kenneth D, deGroot, John F, Pan, Edward, Raizer, Jeffrey J, Kim, Lyndon J, Chmura, Steven J, Robins, H Ian, Connelly, Jennifer M, Battiste, James D, Villano, John L, Wagle, Naveed, Merrell, Ryan T, Wendland, Merideth M, Mehta, Minesh P
Izdano u Cancer (2020)

EPID-25 GERMLINE POLYMORPHISMS IN MGMT INCREASE ABILITY TO MODEL TEMOZOLOMIDE (TMZ)-RELATED MYELOTOXICITY RISK IN PATIENTS WITH GLIOBLASTOMA (GBM) TREATED ON NRG ONCOLOGY/RTOG 0825

od Scheurer, Michael E., Zhou, Renke, Gilbert, Mark R., Bondy, Melissa L., Sulman, Erik P., Yuan, Ying, Liu, Yanhong, Vera-Bolanos, Elizabeth, Wendland, Merideth M., Brachman, David G., Stieber, Volker W., Komaki, Ritsuko R., Flickinger, John C., Kenyon, Lawrence C., Robins, H. Ian, Hunter, Grant K., Crocker, Ian R., Chao, Samuel T., Stella, Philip J., Pugh, Stephanie L., Armstrong, Terri
Izdano u Neuro Oncol (2015)